Introduction
This paper is concerned with chemical diabetes diagnosed for the first time during pregnancy. Chemical diabetes has been defined as an abnormal response to a glucose load but with a fasting capillary blood glucose value not exceeding 130 mg/ 100 ml (FitzGerald and Keen, 1964) . This form of diabetes has been described otherwise as "asymptomatic" or "subclinical" (subgroup "a," FitzGerald and Keen, 1964) .
In our experience chemical diabetes occurs about six times more frequently in pregnancy than the overt variety, so it is important to know if there is an increased risk to the fetus in this mild degree of diabetes, though it is well known there is an increased risk in the prediabetic period in general (Miller, 1945; Malins and FitzGerald, 1965) .
There is a consensus that prolonged pregnancy should be avoided and delivery at or before the expected date should be effected when even mild glucose intolerance has been found. In . The results of the I.V.G.T.T.s were expressed as icrement indices (Duncan, 1956 ) and levels of 2-97 and below were regarded as abnormal. When a patient was found to have an abnormal increment index further antenatal and medical care was undertaken at a weekly combined antenatal diabetic clinic.
Women with a calculated prepregnancy body weight below the 85th percentile on the Kemsley scale and diagnosed at least two weeks before the expected date of delivery were treated with chlorpropamide 100 mg daily for the remainder of the pregnancy. Our experience with larger doses of chlorpropamide is described elsewhere (Cormack et al., 1971; Sutherland et al., 1973) .
When an abnormal test result was found in the last two weeks of pregnancy, admission for surgical induction of labour before term was arranged and no chlorpropamide therapy was given ("untreated group") The capillary blood glucose levels in the first 90 minutes of life in relation to the cord artery levels at birth in infants of chlorpropamide-treated and untreated mothers is shown in fig. 2 . The fall in blood glucose is similar in the two groups. Maternal Age.-The mean age of the chlorpropamide-treated group was 291 ± 6-9 and this was not significantly higher than the untreated group at 27-7 ± 6-5.
Parity.-The mean parity including the index pregnancy of the chlorpropamide-treated group was 3-1 ± 2-1 and this was not significantly higher than the untreated group at 2.6 ± 1-9.
Social Class.-The social class distribution in the two groups was not significantly different.
Fetal Distress.-The incidence of clinical fetal distress defined as the appearance of fresh meconium staining in the liquor amnii and/or a fetal bradycardia of fewer than 120 beats/ min in labour, was not significantly different, being 2% in the chlorpropamide-treated group and 8% in the untreated group.
Induction of Labour.-Surgical induction of labour more than five days before the expected date of delivery was done in 87% of the untreated group compared with 66% in the chlorpropamide-treated group.
Mode of Delivery.-The mode of delivery in the chlorpropamide-treated group and the untreated group respectively was as follows: spontaneous vertex delivery, 78% and 71%; forceps delivery, 6% and 17%; caesarean section, 14% and 12%; assisted breech delivery, 2% and less than 1%.
Perinatal Mortality.-The perinatal mortality in the chlorpropamide-treated group was 40 per 1,000 and in the untreated mothers 8 per 1,000, which is surprisingly lower than the Aberdeen city rate. The rate for the chlorpropamide-treated group, however, represents two deaths in 50 pregnancies, and for the untreated group only one death in 130 pregnancies. Perhaps a better evaluation of the effect of treatment is a comparison of perinatal mortality in the same subjects in treated and untreated pregnancies. Such a comparison is made in table VI. The perinatal mortality in these subjects fell in the chlorpropamide-treated pregnancy from 123 per 1,000 to 40 per 1,000. In the untreated group the perinatal mortality fell from 67 to 8 per 1,000. These differences are not accounted for by the change in mortality between first and subsequent pregnancies in the city of Aberdeen where the rates were 17-3 and 18-3 respectively per 1,000 in 1970. In fig. 3 the insulin responses to the intravenous glucose challenge in the neonate, with the rates of glucose disposal expressed alongside as the increment indices, are shown in the infants of the two groups of mothers. Though the rate of glucose disposal is greater in the infants of the chlorpropamidetreated mothers, the insulin peak is lower and occurs earlier. 
Discussion
This study was initiated only after noting no increase in fetal malformations in women already on oral sulphonylurea therapy at conception and who continued on it through the early months of pregnancy before they reported for antenatal care. Our conclusions that the sulphonylureas had no teratogenic effects in man were supported by the report from the rare diseases subcommittee of the medical and scientific section of the British Diabetic Association (Malins et al., 1964) , and by an earlier report from France (Sterne and Lavieuville, 1963 the fasting blood sugar level to be lower and for the two-hour level after oral glucose to be higher than in the non-pregnant. The rapid I.V.G.T.T. was chosen for this study because it is well tolerated by women in early pregnancy, even those affected by nausea or vomiting at this time, and it avoids the variability of alimentary absorption associated with pregnancy. In view of this and the results of the reproducibility study done, admittedly in normal pregnancies, we prefer the I.V.G.T.T. in pregnancy to all types of oral glucose tolerance test.
It is noteworthy that the I.V.G.T.T. was not found to be reproducible in the puerperium, and this fact must cast doubt on comparative studies of the validity and sensitivity of different forms of glucose tolerance tests during pregnancy in which the postpartum result is used as the standard of reference. This also must raise doubts on the validity of the term gestational diabetes when a normal postpartum test is used as the standard for comparison. We suggest that gestational diabetes should refer to abnormal glucose tolerance during pregnancy when there is no reason to believe that glucose tolerance was other than normal before pregnancy.
Birth weight was used as a possible assessment of the effect of chlorpropamide given to the mother and passing through the placenta to stimulate insulin secretion in the fetus, but a number of other factors can affect birth weight. Allowance has been made for many of these factors in each patient so that the expected quartile range of birth weight can be compared with that actually found. This assessment provided no evidence that chlorpropamide did increase the birth weight, and indeed, we found that the insulin levels were not increased.
The results of this study not only defend the use of chlorpropamide in a dose of 100 mg/day in chemical diabetes in pregnancy, but also point out an apparent advantage in that it appears to improve glucose tolerance in the mother without producing hyperinsulinism in the fetus. There is a suggestion that chlorpropamide may increase the glucose tolerance of the infant by extrapancreatic effects rather than by stimulating the insulin response.
It is very likely that neither of the two neonatal deaths in the chlorpropamide-treated group were attributable to sulphonylurea therapy. The first death occurred in 1963 and was due to the complications of extreme prematurity after failed induction of labour and caesarean section at 32 weeks' gestation, because the diagnosis of intrauterine growth retardation was mistakenly made. In the second case an infant of average weight at term did not survive the surgical correction of a large diaphragmatic hernia at 72 hours of age. The mothers had received chlorpropamide for 11 and six weeks respectively immediately before delivery.
The low perinatal mortality in the chemical diabetic pregnancies studied is probably due to the policy of intensive antenatal care and delivery before term. The figures indicate a greater fetal risk in the years before the chemical diabetes is diagnosed in the mother than in the pregnancy when the glucose intolerance was found. Though it can be argued that the previous pregnancies contained a large proportion of primigravidae with an associated higher incidence of pre-eclampsia and dysfimctional labours, the perinatal mortality in Aberdeen is not higher in first than in subsequent pregnancies. The increased perinatal mortality found in the earlier pregnancies of mothers subsequently shown to have chemical diabetes may be attributable to their relative disadvantage to withstand the stress of labour and an independent neonatal existence, whether or not there coexists the additional insults of pre-eclampsia or dysfunctional labour so characteristic of first pregnancies.
The lower perinatal mortality in the previous pregnancies of the untreated mothers compared with the chlorpropamidetreated mothers is most likely due to a selective factor arising from the fact that previous stillbirth or neonatal death were used as indicators for glucose tolerance testing in pregnancy. This information was available when the patient originally booked in to the antenatal clinic and this would produce a bias in this group to earlier I.V.G.T.T.s in the index pregnancy and a relative diminution of such cases in the untreated group. This bias in selection would also tend to produce a greater number of poor reproducers in the chlorpropamide-treated group.
Because of this and the apparent increase in the signs of fetal distress in labour in the untreated group it has been decided to undertake a double-blind trial of chlorpropamide therapy (100 mg daily) to study its possible clinical role.
